TDRKH
Tudor and KH domain-containing protein
Protein Summary
Participates in the primary piRNA biogenesis pathway and is required during spermatogenesis to repress transposable elements and prevent their mobilization, which is essential for the germline integrity. The piRNA metabolic process mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons. Required for the final steps of primary piRNA biogenesis by participating in the processing of 31-37 nt intermediates into mature piRNAs. May act in pi-bodies and piP-bodies by transferring piRNA precursors or intermediates to or between these granules.
- ENST00000368822
- ENSP00000357812
- ENSG00000182134
- ENST00000368824
- ENSP00000357815
- ENST00000368825
- ENSP00000357817
- ENST00000368827
- ENSP00000357819
- ENST00000458431
- ENSP00000395718
- TDRD2
- TDRD2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
histone modification site profile | 0.86 | ||
tissue sample | 0.62 | ||
trait | 0.61 | ||
microRNA | 0.6 | ||
transcription factor binding site profile | 0.57 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 11.03 (req: < 5)
Gene RIFs: 4 (req: <= 3)
Antibodies: 60 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 11.03 (req: >= 5)
Gene RIFs: 4 (req: > 3)
Antibodies: 60 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 8
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0